Hadasit has signed a $4 million license and cooperation agreement with Poland’s Synektik SA (WSE: STE) to develop new imaging agents for non-invasive diagnosis of cardiovascular diseases.
Synektik will finance research and pre-clinical development of the imaging agents over
The technology is based on a new agent for use in PET/CT scans, which enables a quantitative measurement of blood flow to the heart. This marker also enables doctors to make a qualitative analysis of damage caused after a heart attack, and predict the degree of recovery for the heart after a heart attack or bypass surgery. Implementing the application of this newly-identified marker to diagnose patients with coronary artery diseases could facilitate more accurate diagnoses and treatment methods. The research will be conducted in the Cyclotron and Radiochemistry Unit in Hadassah Hospital Ein Kerem in cooperation with the Synektik’s new R&D facility in Warsaw.
The field of cardiac blood flow measurement addresses a $2 billion annual market.